Eli Lilly and Company (LLY)
Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind
Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026. LLY's acquisition of Kelonia and Orna Therapeutics positions it at the forefront of in vivo CAR-T therapies, targeting major market expansion. The weight loss franchise drives 56% of LLY revenue but faces pricing, legal, and regulatory risks; monitoring volume vs. price dynamics is critical.
Eli Lilly expands genetic medicine capabilities with Kelonia Therapeutics acquisition
Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal aimed at expanding its capabilities in genetic medicines, the companies announced on Monday. The transaction centers on Kelonia's in vivo gene delivery platform, known as iGPS, which uses engineered lentiviral-based particles designed to modify T-cells inside the body.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday.
Eli Lilly Nears Deal for Cancer Biotech
Deal for Kelonia Therapeutics could come as soon as Monday.
Lilly CEO sees weight-loss drugs reaching about half of potential users at peak
Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems and financial constraints, Eli Lilly CEO David Ricks said at a conference on Friday.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
Eli Lilly's Q1 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
Eli Lilly's late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Eli Lilly (LLY) concluded the recent trading session at $905.03, signifying a -1.89% move from its prior day's close.
LLY Stock To $2,000?
Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.
